In the present study, three novel N-benzylpyrrolidine derivatives (<b>3e</b>, <b>3f</b>, and <b>3i</b>), previously identified as dual MAO-A/B inhibitors in silico and in vitro, were pharmacologically evaluated in an acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Here, MAOA is linked to Parkinson disease.